Patent Expiration

Annual Drug Patent Expirations for FARXIGA Farxiga is a drug marketed by Astrazeneca Ab and is included in one NDA. […]

DEXILANT (dexlansoprazole) Takeda pharms usa Patent: 8,722,084 Expiration: Apr 15, 2024 See More … For more information on how DrugPatentWatch

DEXILANT SOLUTAB (dexlansoprazole) Takeda pharms usa Patent: 8,784,885 Expiration: Apr 15, 2024 See More … For more information on how

Annual Drug Patent Expirations for MAVENCLAD Mavenclad is a drug marketed by Emd Serono Inc and is included in one

Annual Drug Patent Expirations for TOBI+PODHALER Tobi Podhaler is a drug marketed by Mylan Speciality Lp and is included in

Annual Drug Patent Expirations for RELISTOR Relistor is a drug marketed by Salix Pharms and Salix and is included in

Annual Drug Patent Expirations for ARIKAYCE+KIT Arikayce Kit is a drug marketed by Insmed Inc and is included in one

Annual Drug Patent Expirations for ORACEA Oracea is a drug marketed by Galderma Labs Lp and is included in one

EXSERVAN (riluzole) Aquestive Patent: 8,603,514 Expiration: Apr 3, 2024 See More … For more information on how DrugPatentWatch can help